Palvella Therapeutics, Inc. Payments to Acquire Investments
Palvella Therapeutics, Inc. (PVLA) reported Payments to Acquire Investments of $0 for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2024-11-13
- Palvella Therapeutics, Inc. payments to acquire investments for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. payments to acquire investments for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. payments to acquire investments for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. payments to acquire investments for the quarter ending 2023-12-31 was $7.57M, a 45.37% increase year-over-year.
- Palvella Therapeutics, Inc. payments to acquire investments for fiscal 2023 was $22.84M, a 52.82% decline from fiscal 2022.
- Palvella Therapeutics, Inc. payments to acquire investments for fiscal 2022 was $48.40M.
- Palvella Therapeutics, Inc. payments to acquire investments for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Palvella Therapeutics, Inc. payments to acquire investments for fiscal 2020 was $41.50M, a 30.04% decline from fiscal 2019.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | $7.57M derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | $7.57M derived: sum of 3 quarters · filed 2024-08-14 | $14.59M derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | $7.57M derived: sum of 2 quarters · filed 2024-05-15 | $14.59M derived: sum of 3 quarters · filed 2024-11-13 | $21.29M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-12-31 | $7.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $14.59M derived: sum of 2 quarters · filed 2024-11-13 | $21.29M derived: sum of 3 quarters · filed 2024-11-13 | $22.84M 10-K · filed 2024-03-29 |
| 2023-09-30 | $7.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $13.73M derived: sum of 2 quarters · filed 2024-11-13 | $15.27M 10-Q · filed 2024-11-13 | $20.47M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $6.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $8.24M 10-Q · filed 2024-08-14 | $13.45M derived: sum of 3 quarters · filed 2024-08-14 | $24.99M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $1.54M 10-Q · filed 2024-05-15 | $6.75M derived: sum of 2 quarters · filed 2024-05-15 | $18.29M derived: sum of 3 quarters · filed 2024-05-15 | $33.38M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $5.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $16.75M derived: sum of 2 quarters · filed 2024-03-29 | $31.84M derived: sum of 3 quarters · filed 2024-03-29 | $48.40M 10-K · filed 2024-03-29 |
| 2022-09-30 | $11.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $26.63M derived: sum of 2 quarters · filed 2023-11-14 | $43.19M 10-Q · filed 2023-11-14 | $43.19M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $15.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $31.64M 10-Q · filed 2023-08-10 | $31.64M derived: sum of 3 quarters · filed 2023-08-10 | $31.64M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $16.56M 10-Q · filed 2023-05-11 | $16.56M derived: sum of 2 quarters · filed 2023-05-11 | $16.56M derived: sum of 3 quarters · filed 2023-05-11 | $16.56M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $0.00 derived: sum of 3 quarters · filed 2023-03-31 | $0.00 10-K · filed 2023-03-31 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $0.00 derived: sum of 2 quarters · filed 2022-11-04 | $0.00 10-Q · filed 2022-11-04 | $321.00K derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | $321.00K derived: sum of 3 quarters · filed 2022-08-04 | $2.97M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-11 | $321.00K derived: sum of 2 quarters · filed 2022-05-11 | $2.97M derived: sum of 3 quarters · filed 2022-05-11 | $15.47M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $321.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $2.97M derived: sum of 2 quarters · filed 2022-03-02 | $15.47M derived: sum of 3 quarters · filed 2022-03-02 | $41.50M 10-K · filed 2022-03-02 |
| 2020-09-30 | $2.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $15.15M derived: sum of 2 quarters · filed 2021-11-02 | $41.18M 10-Q · filed 2021-11-02 | $51.73M derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $12.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $38.52M 10-Q · filed 2021-08-05 | $49.08M derived: sum of 3 quarters · filed 2021-08-05 | $70.84M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $26.03M 10-Q · filed 2021-05-17 | $36.59M derived: sum of 2 quarters · filed 2021-05-17 | $58.35M derived: sum of 3 quarters · filed 2021-05-17 | $77.31M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $10.55M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $32.32M derived: sum of 2 quarters · filed 2021-03-31 | $51.28M derived: sum of 3 quarters · filed 2021-03-31 | $59.32M 10-K · filed 2021-03-31 |
| 2019-09-30 | $21.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $40.73M derived: sum of 2 quarters · filed 2020-11-04 | $48.76M 10-Q · filed 2020-11-04 | $99.33M derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | $18.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $27.00M 10-Q · filed 2020-08-10 | $77.56M derived: sum of 3 quarters · filed 2020-08-10 | $77.36M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $8.04M 10-Q · filed 2020-05-11 | $58.60M derived: sum of 2 quarters · filed 2020-05-11 | $58.40M derived: sum of 3 quarters · filed 2020-05-11 | $114.14M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $50.57M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $50.36M derived: sum of 2 quarters · filed 2020-03-13 | $106.10M derived: sum of 3 quarters · filed 2020-03-13 | $117.58M 10-K · filed 2020-03-13 |
| 2018-09-30 | -$207.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $55.54M derived: sum of 2 quarters · filed 2019-11-12 | $67.02M 10-Q · filed 2019-11-12 | $110.94M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $55.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $67.22M 10-Q · filed 2019-08-09 | $111.15M derived: sum of 3 quarters · filed 2019-08-09 | $111.15M derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-03-31 | $11.48M 10-Q · filed 2019-05-10 | $55.40M derived: sum of 2 quarters · filed 2019-05-10 | $55.40M derived: sum of 3 quarters · filed 2019-05-10 | $55.40M derived: sum of 4 quarters · filed 2019-05-10 |
| 2017-12-31 | $43.92M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $43.92M derived: sum of 2 quarters · filed 2019-03-18 | $43.92M derived: sum of 3 quarters · filed 2019-03-18 | $43.92M 10-K · filed 2019-03-18 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $0.00 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | $0.00 10-K · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |